Related Experiment Video
Updated: Jul 8, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Small molecular CD73 inhibitors: Recent progress and future perspectives
Gong-Hui Ge1, Qiu-Yin Wang1, Zhen-Hao Zhang1
1School of Pharmacy / Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China.
Abstract:
The occurrence and development of the tumor are very complex biological processes. In recent years, a large number of research data shows that CD73 is closely related to tumor growth and metastasis. It has been confirmed that the cascade hydrolysis of extracellular ATP to adenosine is one of the most important immunosuppressive regulatory pathways in the tumor microenvironment. The metabolite adenosine can mediate immunosuppression by activating adenosine receptor (such as A2A) on effector Immune cells and enable tumor cells to achieve immune escape. Therefore, attenuating or completely removing adenosine-mediated immunosuppression in the tumor microenvironment by inhibiting CD73 is a promising approach in the treatment of solid tumors. This paper focuses on the research progress of CD73 enzyme and CD73 small molecule inhibitors, and is expected to provide some insights into the development of small-molecule antitumor drugs targeting CD73.
Insights
Inhibiting CD73, an enzyme crucial for tumor growth and metastasis, can reduce adenosine-mediated immunosuppression. This approach offers a promising strategy for developing novel small-molecule antitumor drugs against solid tumors.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Tumor occurrence and development are complex biological processes.
- CD73 is increasingly recognized for its role in tumor growth and metastasis.
- Extracellular ATP hydrolysis to adenosine is a key immunosuppressive pathway in the tumor microenvironment.
Purpose of the Study:
- To review the research progress on the CD73 enzyme.
- To discuss the development of CD73 small molecule inhibitors.
- To provide insights for developing CD73-targeting antitumor drugs.
Main Methods:
- Literature review of CD73 enzyme research.
- Analysis of studies on CD73 small molecule inhibitors.
- Synthesis of current understanding of adenosine-mediated immunosuppression in tumors.
Main Results:
- CD73 plays a significant role in tumor progression and immune evasion.
- Adenosine, produced by CD73, suppresses immune cells via receptors like A2A.
- Inhibiting CD73 can potentially reverse tumor-induced immunosuppression.
Conclusions:
- Targeting CD73 is a promising strategy for solid tumor treatment.
- CD73 small molecule inhibitors represent a potential therapeutic avenue.
- Further research into CD73 inhibitors could lead to novel antitumor drugs.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity